Pancreatic Cancer clinical trials in Nevada

8 actively recruiting pancreatic cancer trials at 5 sites across Nevada.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …

Sponsor: NRG Oncology

NCT ID: NCT06958328

Sites in Nevada:

Renown Regional Medical Center — Reno, Nevada

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer

NCT ID: NCT06989437

Sites in Nevada:

Renown Health Medical Oncology — Reno, Nevada
Renown Office of Clinical Research — Reno, Nevada
Renown Regional Medical Center — Reno, Nevada

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Sponsor: Revolution Medicines, Inc.

NCT ID: NCT07491445

Sites in Nevada:

Comprehensive Cancer Centers of Nevada — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04858334

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05040360

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

NCT ID: NCT04389632

Sites in Nevada:

Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally …

Sponsor: Amgen

NCT ID: NCT06360354

Sites in Nevada:

Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Nevada:

Carson Tahoe Regional Medical Center — Carson City, Nevada
Cancer and Blood Specialists-Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada - Henderson — Henderson, Nevada
Comprehensive Cancer Centers of Nevada-Horizon Ridge — Henderson, Nevada
Las Vegas Cancer Center-Henderson — Henderson, Nevada

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20